pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,000 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1891Endpoints1465Fierce Biotech779BioSpace767BioPharma Dive555raps254onclive165fda recalls
therapy area
allOncology13094Rare Disease3387Immunology3069Cardiology2866Hematology2335Pulmonology2299Vaccines
  • Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapy
    Compass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…
    BioPharma Dive · 2h agoRegulatoryNeutral↗ source
  • Erasca reports 44% response in KRAS-mutated pancreatic cancer, eyes Phase 3 trial
    Erasca announced that 44% of patients with KRAS-mutated pancreatic cancer showed a response to its experimental drug ERAS-0015 in a small Phase 1 study. The company said the treatment was well tole…
    BioPharma Dive · 5h agoPositive readoutNeutral↗ source
← prev
page 1 of 120
next →
125
fda medwatch117
globenewswire health73
fda press62
1882
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • China-origin biotech deals and IPOs surge as investors reap early returns, while Summit Therapeutics shares slump
    Biotech firms built around medicines originating in China have accelerated both acquisitions and initial public offerings this year, according to recent data visualizations. The large pool of Chin…
    BioPharma Dive · 10h agoDealNeutral↗ source
  • Sanofi considers Insmed acquisition as FDA criticizes J&J bladder cancer drug claims; Japan eyes higher drug prices
    Sanofi is reportedly evaluating a possible takeover of Insmed, signaling continued consolidation activity in the biotech sector. The U.S. Food and Drug Administration has issued a warning to Johns…
    STAT · 8h agoDealNeutral↗ source
  • Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filing
    Celldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…
    BioPharma Dive · 9h agoNegative readoutNegative↗ source
  • FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are ranked
    The Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…
    STAT · 12h agoRegulatoryNeutral↗ source
  • Big pharma say they will stop opening new trial sites in Xinjiang and Chinese military hospitals
    Several of the world’s largest pharmaceutical companies told a U.S. House Select Committee on China that they will not start new clinical trial sites in the Xinjiang region of China or at hospitals…
    STAT · 22h agoRegulatoryNegative↗ source
  • Alterome reports early Phase 1 data for KRAS-targeted therapy in pancreatic, lung and colon cancers
    Alterome has unveiled preliminary Phase 1 data for its experimental KRAS-targeted therapy. The drug is designed to hit a spectrum of KRAS mutations that drive several solid tumours. The early stud…
    STAT · 8h agoPositive readoutNeutral↗ source
  • UnitedHealth sues CMS over lowered 2027 Medicare Advantage star ratings
    UnitedHealth Group has filed a lawsuit against the Centers for Medicare & Medicaid Services seeking to overturn the agency’s lowered star ratings for its Medicare Advantage plans for 2027. The sui…
    STAT · 14h agoRegulatoryNegative↗ source
  • FDA outlines inspection focus on risk management for combination product manufacturers
    FDA officials said that manufacturers using a streamlined CGMP approach for combination products should expect the agency to closely scrutinize their risk management activities. The remarks were d…
    raps · 22h agoRegulatoryNeutral↗ source
  • Medicare launches pilot to test nutrition and exercise programs as preventive care for chronic disease
    Department of Health and Human Services announced that fifteen groups across the United States will participate in a Medicare pilot aimed at evaluating lifestyle interventions for chronic disease p…
    STAT · 3h agoRegulatoryPositive↗ source
  • Scientists study blood markers for chronic traumatic encephalopathy using samples from 21 football players
    Researchers collected blood from 21 current football players and arranged for their brains to be donated after death to support chronic traumatic encephalopathy (CTE) research. The team is analyzi…
    STAT · 8h agoNeutral↗ source
  • Ailux appoints former Johnson & Johnson executive Lloyd Miller as chief medical officer
    Ailux announced the hiring of Lloyd Miller as its new chief medical officer. Miller comes from Johnson & Johnson where he served as senior vice president and global head of translational science &…
    STAT · 6h agoNeutral↗ source
  • Exercise should be prescribed alongside rest for concussion recovery, author argues
    The author recounts a severe brain injury that left him in a coma, caused significant muscle loss and left-side weakness, and made simple tasks like getting out of a bathtub a struggle. He began a…
    STAT · 12h agoPositive↗ source
  • Patient coalition urges more agency for participants in brain-implant trials
    A new report released by the BCI Pioneers Coalition outlines 13 recommendations aimed at improving how brain‑computer interface trials are conducted. The guidance targets startups, researchers and…
    STAT · 12h agoNeutral↗ source
  • MAHA Institute’s 2025 tax filing reveals cash reserves fell to $171,000 after spending over $1 million
    The MAHA Institute, a nonprofit created to support Robert F. Kennedy Jr.’s health agenda, reported in its 2025 IRS filing that it began the year with nearly $1.3 million in cash and ended with just…
    STAT · 1h agoNegative↗ source
  • Only 10% of surgeons in East and Central Africa are women, highlighting gender gap in global surgery
    An opinion piece notes that women comprise just one‑tenth of the surgical workforce across twelve COSECSA member countries, a proportion that has not changed in years. The author observed a documen…
    STAT · 12h agoNegative↗ source
  • ICE detention of Princeton scientist rattles academia
    A graduate student who is a scientific researcher at Princeton was detained by ICE while traveling home after presenting at a neuroscience conference.
    STAT · 1h ago↗ source
  • US panel warns China’s biotech plan could dominate sector and threaten drug supply chain
    A congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
    BioPharma Dive · 1d agoRegulatoryNegative↗ source
  • FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravis
    The Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…
    BioPharma Dive · 1d agoApprovalPositive↗ source
  • FDA approves treatments for four rare diseases; Pfizer inks $2.6 billion China licensing deal for CAR‑T therapy
    The U.S. Food and Drug Administration has granted approval for drugs targeting four distinct rare diseases, expanding therapeutic options for patients with limited treatment choices. In a separate…
    raps · 1d agoApprovalPositive↗ source
  • Merck partners with Isomorphic Labs to use AI for discovering oncology drug candidates
    Merck announced a research collaboration with Isomorphic Labs, an artificial‑intelligence drug design firm, to explore small‑molecule candidates aimed at an undisclosed oncology target. Isomorphic…
    STAT · 1d agoDealPositive↗ source
  • Merck teams with Isomorphic Labs to discover new oncology small-molecule candidates
    Merck and Isomorphic Labs announced a research collaboration aimed at discovering small-molecule drugs for an undisclosed oncology target. The partnership will combine Isomorphic’s AI-driven drug…
    STAT · 1d agoDealPositive↗ source
  • U.S. loses measles elimination status as outbreaks claim first deaths in decades
    The Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…
    STAT · 23h agoNegative↗ source
  • Study finds malaria antibody L9LS reduces vaccine response in infants
    Researchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
    STAT · 1d agoNegative readoutNegative↗ source